BriaCell Therapeutics Corp BCTX shares are trading higher on Wednesday after the company announced it is expanding its breast cancer platform into prostate, melanoma and lung cancers.
The expansion includes Bria-Pros for prostate cancer, Bria-Mel for melanoma and Bria-Lung for lung cancer and the company anticipates commencing clinical trials for these therapies in 2022.
BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer.
At the time of publication, shares of BriaCell Therapeutics were trading 18.6% higher at $7.15. The stock has a 52-week low of $2.81 and a 52-week high of $9.00.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
